This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Pancreatic Cancer
and you are
over 18
years old
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Provided treatments

  • Procedure: Stereotactic body radiotherapy
  • Drug: Iodixanol
  • Drug: Iohexol

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01326364. The sponsor of the trial is Stanford University and it is looking for 6 volunteers for the current phase.
Official trial title:
Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection